Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N.
Johnston R, et al. Among authors: cummins e.
Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020.
Health Technol Assess. 2017.
PMID: 28105986
Free PMC article.
Review.